Go offline with the Player FM app!
BoB@JPM: Owen Hughes & Brad Sitko, XOMA Royalty
Manage episode 469405130 series 2739469
We love to hear from our listeners. Send us a message.
On this episode of the Business of Biotech, recorded on-site at the 2025 JP Morgan Healthcare Conference, we explore a new approach to biotech financing with XOMA Royalty's Owen Hughes and Brad Sitko. The CEO and CIO, respectively, share an innovative royalty aggregation model that mitigates risk while enabling immediate capital access to biotech firms. We learn the differences between royalty financing and equity-based funding, how the model addresses traditional risk in biotech financing, the evolution of XOMA's business model, and much more.
The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Chapters
1. Introduction to Zonelart Royalty (00:00:00)
2. Meet the Founders: Owen Hughes and Brad Sipko (00:04:39)
3. What is Royalty Aggregation? (00:10:51)
4. Benefits of Royalty Financing vs. Equity (00:20:30)
5. Risk Management in Biotech Investments (00:30:45)
6. The Evolution of Zonelart Royalty (00:42:15)
7. The Role of Experience in Investment Decisions (00:55:00)
8. Future Trends in Biotech Financing (01:10:40)
9. Closing Thoughts and Takeaways (01:20:00)
254 episodes
Manage episode 469405130 series 2739469
We love to hear from our listeners. Send us a message.
On this episode of the Business of Biotech, recorded on-site at the 2025 JP Morgan Healthcare Conference, we explore a new approach to biotech financing with XOMA Royalty's Owen Hughes and Brad Sitko. The CEO and CIO, respectively, share an innovative royalty aggregation model that mitigates risk while enabling immediate capital access to biotech firms. We learn the differences between royalty financing and equity-based funding, how the model addresses traditional risk in biotech financing, the evolution of XOMA's business model, and much more.
The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Chapters
1. Introduction to Zonelart Royalty (00:00:00)
2. Meet the Founders: Owen Hughes and Brad Sipko (00:04:39)
3. What is Royalty Aggregation? (00:10:51)
4. Benefits of Royalty Financing vs. Equity (00:20:30)
5. Risk Management in Biotech Investments (00:30:45)
6. The Evolution of Zonelart Royalty (00:42:15)
7. The Role of Experience in Investment Decisions (00:55:00)
8. Future Trends in Biotech Financing (01:10:40)
9. Closing Thoughts and Takeaways (01:20:00)
254 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.